2 results
Approved WMOCompleted
To evaluate the effects of AMT-101 in combination with adalimumab on UC disease activity as measured by symptoms, endoscopy, histology, and biomarkers. To evaluate the safety and tolerability of oral AMT-101 over 8 weeksTo assess the PK parameters…
Approved WMORecruiting
To evaluate diagnostic accuracy of PSMA-PET/CT and FACBC-PET/CT in detection of lymph node metastases in initial staging of intermediate- to high-risk PCa.